Holen Sie sich die Stockscreener-App
7.39
2.25%
-0.17
Vorhandelsmarkt:
7.50
0.11
+1.49%
Schlusskurs vom Vortag:
$7.56
Offen:
$7.56
24-Stunden-Volumen:
887.79K
Relative Volume:
0.38
Marktkapitalisierung:
$444.40M
Einnahmen:
$216.11M
Nettoeinkommen (Verlust:
$-220.47M
KGV:
-1.9779
EPS:
-3.7363
Netto-Cashflow:
$-110.44M
1W Leistung:
+8.04%
1M Leistung:
+5.57%
6M Leistung:
+66.44%
1J Leistung:
+61.00%
1-Tages-Spanne:
$7.35
$7.58
1-Wochen-Bereich:
$6.80
$7.59
52-Wochen-Spanne:
$3.8092
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Firmenname
Vanda Pharmaceuticals Inc
Sektor
Branche
Telefon
202-734-3400
Adresse
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
7.39 | 444.40M | 216.11M | -220.47M | -110.44M | -3.7363 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-05 | Eingeleitet | Truist | Buy |
| 2025-11-05 | Eingeleitet | B. Riley Securities | Buy |
| 2024-10-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Herabstufung | Jefferies | Buy → Hold |
| 2021-05-12 | Eingeleitet | BofA Securities | Buy |
| 2021-01-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-03-16 | Herabstufung | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-08-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Bestätigt | Jefferies | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-09-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-09-14 | Bestätigt | Piper Jaffray | Overweight |
| 2017-06-27 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-05-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-09 | Eingeleitet | Aegis Capital | Buy |
| 2016-10-06 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten
Vanda Pharmaceuticals (VNDA) Launches Nereus for Motion Sickness Relief - GuruFocus
Vanda Pharmaceuticals shares rise on Nereus commercial launch By Investing.com - Investing.com Australia
D.C.'s Vanda Pharmaceuticals launches first new prescription motion sickness drug in decades - The Business Journals
Vanda launches motion sickness drug after 40-year gap By Investing.com - Investing.com South Africa
Vanda launches motion sickness drug after 40-year gap - Investing.com
Vanda Pharmaceuticals announces U.S. commercial availability of Nereus(TM) (tradipitant), the first new pharmacologic treatment for people with motion sickness in more than 40 years - marketscreener.com
Vanda Pharmaceuticals Announces U.S. Commercial Availability Of Nereus™ (Tradipitant), The First New Pharmacologic Treatment For People With Motion Sickness In More Than 40 Years - TradingView
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline - Investing.com
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
Vanda Pharmaceuticals (VNDA) Launches Nereus for Motion Sickness Prevention - GuruFocus
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years - The Malaysian Reserve
Vanda Pharmaceuticals (VNDA) Launches New Motion Sickness Drug, Stock Rises - GuruFocus
NEREUS now available for online purchase as Vanda Pharmaceuticals expands access - Traders Union
MSN Money - MSN
Gastroparesis Market: Investment-Ready Growth Trends to 2034 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma - Barchart.com
Gastroparesis Market: Investment-Ready Growth Trends to 2034 - openPR.com
Why did Vanda Pharmaceuticals stock slide 7% pre-market today? - MSN
VNDA Stock Price, Quote & Chart | VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) - ChartMill
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - BioSpace
Vanda Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Vanda sets May 6 earnings release, investor call after market close - Stock Titan
BlackRock (NASDAQ: VNDA) reports 2.5M shares beneficially owned in 13G/A - Stock Titan
Vanda Pharmaceuticals (VNDA) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
VNDA Q1'26 Earnings: revenue estimate is 54.98M USD - TradingView
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence - The Malaysian Reserve
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Vanda Pharmaceuticals Publishes Imsidolimab Research Findings - Intellectia AI
Vanda Sues FDA Over Suspended Drug Study for Stomach Disorder - Bloomberg Law News
Vanda Pharmaceuticals announces the publication of "Efficacy and - GuruFocus
Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
The Christmas party is still ongoing in these stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell - MSN
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
HC Wainwright & Co. Reiterates Vanda Pharmaceuticals (VNDA) Buy Recommendation - MSN
Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti for bipolar, schizophrenia - MSN
Vanda Pharmaceuticals (VNDA) grants director 57,101 time-based RSUs - Stock Titan
Vanda Pharmaceuticals (NASDAQ: VNDA) director files initial Form 3 ownership - Stock Titan
Vanda Pharmaceuticals | DEFA14A: Others - Moomoo
Vanda Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
[ARS] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan
Executive pay, board votes and pipeline in Vanda (NASDAQ: VNDA) 2026 proxy - Stock Titan
Vanda Pharmaceuticals adds Charles Duncan to board By Investing.com - Investing.com India
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board o - GuruFocus
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to Board of Directors to Drive Growth and Innovation in CNS Therapies 1 - Minichart
Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):